Monitor for early human biomarker data from the Phase 2/3 safety run-in expected Q4 2026, which could serve as a proof-of-concept catalyst. The IND filing and Phase 2 expansion initiation in Q1 2027 are key regulatory milestones. Given the micro-cap status and no revenue, any positive clinical data could drive significant volatility.
Price Chart
Executive Summary
Silexion Therapeutics published an updated corporate presentation on August 10, 2026, detailing its lead product candidate SIL204, a first-in-class siRNA targeting KRAS-driven cancers. The presentation includes an updated clinical timeline: Phase 2/3 trial initiated July 2026 in locally advanced pancreatic cancer (LAPC), early human biomarker data expected Q4 2026, IND application planned Q1 2027, Phase 2 expansion Q1 2027, and Phase 3 confirmatory initiation Q3 2030. No financial data was disclosed. This is a routine clinical-stage pipeline update for a pre-revenue micro-cap biotech.
Key Facts
- Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer (LAPC) initiated July 2026 with regulatory approval from Israel's MoH and Germany's BfArM.
- Early human ctDNA biomarker data expected Q4 2026; IND application planned Q1 2027.
- Toxicology completed: safety margins up to 11-fold over clinical starting dose; no systemic organ toxicity observed.
- Preclinical data show broad KRAS mutation silencing (G12D/V/C/R/A, G13D, Q61H) at sub-nanomolar IC50 values.
- SIL204 combines intratumoral and systemic delivery to target both primary tumor and micrometastases.
- Strategic collaboration with Catalent and Axolabs for GMP clinical supply.
- Company has never generated revenue from product sales; market cap ~$2M.
- Intellectual property: expected protection until 2043 with possible extension to 2048.
Financial Impact
No financial data reported; pre-revenue development-stage company with ~$2M market cap.
Risk Factors
- Development-stage company with no revenue and limited operating history.
- RNAi therapeutic approach for oncology is unproven at commercial scale.
- Phase 2/3 trial is early; safety and efficacy data are not yet available.
- Potential dilution risk given small market cap (~$2M) and cash needs for ongoing clinical trial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178913-26-003966 |
| Document: zk2635901.htm | 0001178913-26-003966 |
| Document: 0001178913-26-003966-index-headers.html | 0001178913-26-003966 |
| Document: 0001178913-26-003966-index.html | 0001178913-26-003966 |
| Document: 0001178913-26-003966.txt | 0001178913-26-003966 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1708 (−11.05%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1708 (+35.01%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1708 (−38.34%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1708 (+38.41%) |
Sep 29, 2026 27d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1708 (+46.29%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1708 (+46.36%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1708 (−31.24%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1708 (−31.24%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1708 (+31.24%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1708 (+59.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers